Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sugamata

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncology|January 1, 1992
Intersite variation of estrogen receptors in human breast cancers and response to endocrine therapy. Which section of a large tumor is the best for estrogen receptor assay?Y Iino, N Sugamata, M Maemura, et al.
Anticancer Research|September 1, 1995
Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancerT Yokoe, Y Iino, N Sugamata, et al.
Anticancer Research|July 1, 1993
Subcutaneous mastectomy with axillary dissection for early breast cancerY Iino, T Ishikita, T Takeo, et al.
Anticancer Research|September 1, 1994
Nonpalpable breast cancerY Iino, N Sugamata, H Aoyagi, et al.
International Journal of Molecular Medicine|July 14, 1999
The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancerY Koibuchi, N Sugamata, Y Iino, et al.
Anticancer Research|November 1, 1994
Clinical significance of first line treatment in recurrent breast cancerY Iino, H Aoyagi, T Takeo, et al.
Anticancer Research|July 1, 1995
Subcutaneous mastectomy with axillary dissection plus breast reconstruction using latissimus dorsi myocutaneous flap (or latissimus dorsi muscle) for breast cancerY Iino, H Takei, T Andoh, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic miceY Iino, Y Takai, T Ando, et al.
Anticancer Research|May 1, 1995
Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancerY Iino, T Takeo, N Sugamata, et al.
Anticancer Research|May 6, 1998
Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in ratsY Iino, T Karakida, N Sugamata, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncology|January 1, 1992
Intersite variation of estrogen receptors in human breast cancers and response to endocrine therapy. Which section of a large tumor is the best for estrogen receptor assay?Y Iino, N Sugamata, M Maemura, et al.
Anticancer Research|September 1, 1995
Phase II trial of mitoxantrone, doxifluridine and medroxyprogesterone acetate as second-line treatment for anthracycline-resistant metastatic breast cancerT Yokoe, Y Iino, N Sugamata, et al.
Anticancer Research|July 1, 1993
Subcutaneous mastectomy with axillary dissection for early breast cancerY Iino, T Ishikita, T Takeo, et al.
Anticancer Research|September 1, 1994
Nonpalpable breast cancerY Iino, N Sugamata, H Aoyagi, et al.
International Journal of Molecular Medicine|July 14, 1999
The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancerY Koibuchi, N Sugamata, Y Iino, et al.
Anticancer Research|November 1, 1994
Clinical significance of first line treatment in recurrent breast cancerY Iino, H Aoyagi, T Takeo, et al.
Anticancer Research|July 1, 1995
Subcutaneous mastectomy with axillary dissection plus breast reconstruction using latissimus dorsi myocutaneous flap (or latissimus dorsi muscle) for breast cancerY Iino, H Takei, T Andoh, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
A new triphenylethylene derivative, TAT-59; hormone receptors; insulin-like growth factor 1; and growth suppression of hormone-dependent MCF-7 tumors in athymic miceY Iino, Y Takai, T Ando, et al.
Anticancer Research|May 1, 1995
Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancerY Iino, T Takeo, N Sugamata, et al.
Anticancer Research|May 6, 1998
Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in ratsY Iino, T Karakida, N Sugamata, et al.
Pageof 3